Biosimilar User Fee Collections Drop Well Below Estimates, But US FDA Not Worried

The US Food and Drug Administration's biosimilar user fee program booked a substantial loss in fiscal year 2018 compared to estimates, but the agency is not worried about its ongoing health.

Cash collections were estimated to be $40.2m that year, but the agency only received $29.2m, according to program financial data discussed 7 June during an FDA public meeting on...